1Research Scholar, Department of Pharmaceutical sciences, Suresh Gyan Vihar University, Jaipur (India)
2Department of Pharmaceutics, Sudhakarrao Naik Institute of Pharmacy, Pusad, Dist. Yavatmal, (India)
*Corresponding Author E-mail: manojnitalikar@lycos.com
Online published on 31 October, 2013.
Skin delivery of NSAIDs offers several advantages over the oral route associated with potential side effects. The present research has been undertaken with the aim to develop a topical gel formulation of Meloxicam, which would attenuate the gastrointestinal relater toxicities associated with oral administration. Meloxicam is a nonsteroidal anti-inflammatory drug. It has anti-inflammatory, analgesic and antipyretic activity through inhibition of prostaglandinsynthetase, via inhibition of cyclooxygenase enzymes. This study was designed to enhance the solubility of Meloxicam by preparing its inclusion complex with β-cyclodextrin and formulating gels using Carbopol 940 and HPMC E 6. The gels were evaluated for release through goat abdominal skin. It was observed that the formulation containing complex (DCG 2) was good in all respects.
Meloxicam, β-cyclodextrin, Meloxicam-β-CD-Complex, gel, goat abdominal skin
